Figure 6.
The immunomodulatory properties of PapMV are maintained when treatment is given two days after tumor implantation. (a) Injection schedule for metastasis implantation model in Balb/c mice (created with BioRender.com). Balb/c mice were injected IV with 3×105 4T1 cells, 24 hours later they were treated with an α-ifnar or IgG1 control antibody. 24 hours later they were injected IV with PapMV or TRIS. Mice were euthanized at D3 or D17. (b) Images and (c) numbers of lung metastases at D17 following treatment with PapMV or TRIS. At D3, (d-h) lungs and (i-j) blood were harvested for flow cytometric cell labeling. In the lungs, proportions of (d) myeloid cells, (e) total monocytes, (f) inflammatory monocytes, (g) resident monocytes, and (h) macrophages were determined based the cell population indicated on the Y axis. In the blood, the proportion of (i) myeloid cells and (j) inflammatory monocytes were determined based on total CD45+ immune cells. Serum was collected 24h following PapMV treatment and (k) ifn-α, (l) tnf-α, (m) IL-6 and (n) MCP-1 concentrations were measured. Values are means ± SEM and compiled from of two independent experiments (n = 6).